Research Analysts' Recent Ratings Updates for Novavax

Research Analysts' Recent Ratings Updates for Novavax


They now have a $1.50 price target on the stock. According to Zacks, "NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases.



from Biotech News